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Introduction
Glucose homeostasis enlists complex mechanisms, co-ordinating regulation of several organs, including the liver, pancreas, adipose tissue, muscle and kidney. The kidneys play an important role in regulating glucose homeostasis by preventing glucose excretion (Vallon, 2015) . Filtered glucose is reabsorbed back into the blood circulation via the renal proximal tubule using two steps requiring renal glucose transporters. First, glucose is taken up from the tubular lumen into the renal tubular cells via sodium-glucose cotransporters (SGLTs), including SGLT2 and SGLT1, localized on the brush border membrane of the proximal tubule S1/S2 and S3 segments, respectively (Wright, 2001) . SGLT-mediated glucose transport is a secondary active process, moving glucose into the cell using energy derived from the sodium electrochemical potential gradient across the brush border membrane, and is maintained by the transport of intracellular sodium into the blood via Na + -K + -ATPase at the basolateral membrane. In contrast, glucose transporter (GLUT) facilitates passive transport of glucose across membranes and does not require an energy source (Brown, 2000) . Although SGLT1 is expressed in renal proximal tubular cells, SGLT2 plays more significant roles in apical glucose uptake (Hediger et al. 1995; Wright, 2001) .
Mutations of SGLT2 (SLC5A2) have been found to be associated with impaired renal glucose reabsorption leading to glucosuria with no intestinal phenotype and kidney function impairment (Santer & Calado, 2010) . The expression and function of SGLT2 was increased in type 2 diabetes (Rahmoune et al. 2005) and diabetic rodent models (Vallon et al. 2013) . The mechanisms involved in upregulation of SGLT2 in type 2 diabetes are little known. Studies reported that SGLT2 activity is stimulated by protein kinase C (PKC) and protein kinase A (PKA; Ghezzi & Wright, 2012) , whereas expression of SGLT2 is upregulated by hepatocyte nuclear factor-1α (Freitas et al. 2008) . The involvement of SGLT2 in type 2 diabetes suggests the possibility of development of SGLT2 inhibitors as diabetic drugs. Several lines of evidence suggest that SGLT2 inhibitors reduce hyperglycaemia in type 2 diabetes via an insulin-independent mechanism in the absence of clinically relevant hypoglycaemia (Chao & Henry, 2010) .
Liver X receptors (LXRs) are members of a nuclear receptor family consisting of two isoforms, LXRα and LXRβ (Willy et al. 1995) . Liver X receptors play a major role in glucose, lipid and cholesterol metabolism (Costet et al. 2000; Repa et al. 2002; Tontonoz & Mangelsdorf, 2003; Mitro et al. 2007 ). Activation of LXRs controls glucose homeostasis by reducing liver glucose output and increasing peripheral glucose elimination. Wild-type mice treated with an LXR agonist downregulate gluconeogenesis in their livers through a decrease in the expression of key enzymes, such as phosphoenolpyruvate carboxykinase and glucose-6-phosphatase (Ding et al. 2014) . In addition to energy metabolism, LXR activation has been reported to regulate kidney function. Liver X receptors have been shown to regulate membrane transport proteins, including cystic fibrosis transmembrane conductance (Raksaseri et al. 2013) , epithelial sodium channel , organic anion transporter 1 (Kittayaruksakul et al. 2012) , sodium-phosphate cotransporter (Caldas et al. 2011) and aquaporins 1 and 2 (Gabbi et al. 2012; Lu et al. 2016) .
It is possible, therefore, that LXR activation regulates glucose transport in the renal proximal tubular cells by modulating transport function of SGLT2. Although pharmacological inhibition of SGLT2 is found to improve diabetes, downregulation of SGLT2, such as a reduction of protein expression, might provide be a new treatment for diabetes mellitus. The present study investigated the role of LXRs in regulation of SGLT2-mediated glucose uptake in human renal proximal tubular cells. Secondary antibody, horseradish peroxidase-conjugated goat anti-rabbit IgG, and hyperfilm enhanced chemiluminescence (ECL) were purchased from Millipore (Bangkok, Thailand). All other chemicals were purchased from standard sources and were generally the highest purity available.
Methods

Chemicals
Cell culture
Human renal proximal tubular cell lines, including human kidney-2 (HK-2) and RPTEC/TERT1 cells, were obtained from American Type Culture Collection (ATCC). HK-2 cells were cultured in low-glucose Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS; Millipore), 100 U ml −1 penicillin and 100 μg ml −1 streptomycin. RPTEC/TERT1 cells were cultured in a 1:1 mixture of DMEM and Ham's F-12 nutrient mix supplemented with 5 μg ml −1 insulin, 5 μg ml
transferrin, 5 ng ml −1 sodium selenite, 100 U ml
penicillin, 100 μg ml −1 streptomycin, 10 ng ml −1 epithelial P. Chonlaket and others growth factor and 36 ng ml −1 hydrocortisone. Cells were cultured routinely in a T75 flask at 37°C in air enriched with 5% CO 2 and 95% humidified atmosphere.
Cell viability assay
Cell viability was evaluated by measuring the mitochondrial activity of the cells with the MTT assay. HK-2 cells were seeded on 96-well tissue culture microplates at 1.5 × 10 4 cells per well for 48 h, and then the cells were incubated with different treatments for 24 h. After incubation, the medium was replaced with 100 μl per well of MTT solution (0.5 mg ml −1 in serum-free medium) and further incubated for 2 h. The MTT solution was removed, and the formazan salt form was dissolved by 100 μl per well of DMSO, and the absorbance at 570 nm was measured by a microplate reader. The data are shown as the percentage of cell viability compared with the control group.
Measurement of SGLT2-mediated glucose uptake in renal proximal tubular cells
The SGLT2-mediated glucose uptake was determined using a radioactive labelled glucose analogue, [
3 H]-2DG, as a tracer. The accumulation of the radioactive labelled glucose analogue in the cells was measured by scintillation counting. The cells were seeded on 24-well plates to allow the cells to form a confluent monolayer. Then, the cell monolayer was washed twice with 1 ml of glucose transport buffer solution (140 mM NaCl, 5 mM KCl, 2.5 mM CaCl 2 , 1 mM MgSO 4 , 1 mM KH 2 PO 4 and 10 mM Hepes) and incubated for a further 15 min. After the pre-incubation period, 200 μl of glucose transport buffer containing 10 nM [ 3 H]-2DG and 10 μM cytochalasin B, a non-selective inhibitor of GLUTs, was added to each well for 10 min. Cells were washed three times with 1 ml ice-cold transport buffer to stop transport activity of the transporter. The cells were then solubilized with 0.4 N NaOH in 10% SDS for at least 4 h, and neutralized with 1 N HCl. The samples were transferred to scintillation vials for measurement of accumulated radioactivity. Uptake rates were expressed as moles per square centimetre of surface area of confluent monolayer. The SGLT2-mediated uptake was calculated by subtraction of the total uptake of [ 3 H]-2DG from the uptake of [ 3 H]-2DG in the presence of 10 μM canagliflozin.
Kinetic study
Cells were incubated with glucose transport buffer containing [ 3 H]-2DG plus various concentrations of non-radioactive 2-deoxyglucose (10-10,000 μM) for 10 min. Cellular uptake was calculated as femtomoles per minute per square centimetre of the confluent monolayer surface. The kinetic parameters, including the maximal rate of transport (J max ) and the concentration of unlabelled glucose that resulted in half-maximal transport (K t ), were determined by Michaelis-Menten kinetics of competitive interaction of unlabelled and labelled [
3 H]-2DG as defined by the following equation (Malo & Berteloot, 1991) : [T] represents the concentration of unlabelled glucose in the transport reaction; and C is a constant that represents the component of total glucose uptake that is not saturated over the range of substrate concentrations tested.
Electrophysiological study
Short-circuit current (I sc ) was used to monitor the electrogenic transport function of SGLT in polarized human renal proximal tubular cells, RPTEC/TERT1 cells. Cells were cultured on a Snapwell insert for at least 21 days before experiments. Only the cell monolayers that developed resistance >100 .cm 2 were used for transport studies. The confluent monolayer was assembled in an Ussing chamber, and the spontaneous potential difference across the monolayer was clamped to 0 mV. The I sc was recorded continuously using a VC600 voltage clamp (Physiologic Instruments, San Diego, CA, USA) with Ag/AgCl electrodes and 3 M KCl agar bridges. The apical and basolateral sides of the cell monolayers were bathed in physiological solution containing (mM): 117 NaCl, 25 NaHCO 3 , 4.7 KCl, 1.2 MgSO 4 , 2.5 CaCl 2 , 1.2 KH 2 PO 4 and 11 D-glucose at pH 7.4. The solution was maintained at 37°C and bubbled with 95% O 2 and 5% CO 2 to maintain pH. To measure SGLT2-mediated Na + /glucose flux, 10 μM of cangliflozin was added into the apical part. The transport function of SGLT2 is shown as the canagliflozin-sensitive I sc .
Western blot analysis
Cells were lysed with modified RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM NaF, 1 mM Na 2 VO 4 , 1 mM phenylmethylsulfonyl fluoride and protease inhibitor cocktail). After 20 min of incubation on ice and being centrifuged at 11,269g for 20 min, the supernatants were collected and the protein concentration was measured by the BCA (bicinchoninic acid) method. Equal amounts of protein samples were mixed with 5× loading dye buffer and heated for 5 min at 95°C. Protein was resolved by SDS-PAGE and, subsequently, transferred to a nitrocellulose membrane by electro-blotting. Membranes were incubated overnight at 4°C with anti-SGLT1 and anti-SGLT2 (Santa Cruz), anti-actin (Sigma Aldrich) and anti-GAPDH (Cell Signaling). Signals were detected using the enhanced chemiluminescence procedure.
Real-time PCR
PCR amplification was then performed using the KAPA SYBR FAST master mix (KAPA Biosystems, Woburn, MA, USA). The primers (forward and reverse, respectively) for hSGLT1 and hSGLT2 used in this study are as follows: hSGLT1 5 -CATTCGCAGGACAGCTCTTAC-3 and 5 -ACCAAAACCAGGGCATTCCA-3 , hSGLT2 5 -AGTG CCTGCTCTGGTTTTGT-3 and 5 -GAGGCTGTGGCT TATGGTGT-3 , and hGAPDH 5 -CAAGCTCATTTCCTG GTATGAC-3 and 5 -GTGTGGTGGGGGACTGAGTGTG G-3 . The values of cycle threshold (C T ) were obtained from an ABI Prism 7500 Sequence Detection System (Applied Biosystems), and the mRNA expressions were determined using the 2 − C T method (Livak & Schmittgen, 2001) .
Results
Liver X receptor agonists inhibit SGLT2-mediated glucose uptake in renal proximal tubular cells
As previously demonstrated, LXRα and LXRβ are expressed and activated in the presence of an LXR agonist in HK-2 cells (Fongsupa et al. 2015) . Expression of SGLT1 and SGLT2 in HK-2 cells was determined by qPCR. Our data showed that mRNA expression of SGLT2 was about ninefold higher than that of SGLT1. The transport function of SGLT2 in HK-2 cells was verified using phlorizin and canagliflozin, a non-selective and a selective SGLT2 inhibitor, respectively. The results showed that canagliflozin significantly inhibited [ 3 H]-2DG uptake in this cell model. Phlorizin produced slightly more inhibition of [ 3 H]-2DG uptake compared with canagliflozin, indicating that SGLT2 plays a major role in glucose uptake (Fig. 1A) .
Next, the effect of LXR agonists on SGLT2-mediated uptake in HK-2 cells was determined. A confluent cell monolayer of HK-2 cells was fasted for 12 h and treated with vehicle (0.1% DMSO) or various concentrations of synthetic LXR agonists, T0901317 (1-10 μM) or GW3965 (1-5 μM), for 24 h in serum-free medium. At the end of the incubation period, 10 min uptake of glucose into HK-2 cells was measured. As shown in Fig. 1B , T0901317 or GW3965 inhibited SGLT2-mediated [ 3 H]-2DG transport in a concentration-dependent manner.
To verify whether a decrease in the transport activity of HK-2 cells was caused by toxicity, HK-2 cells were incubated for 24 h with vehicle (0.1% DMSO) or the LXR agonists T0901317 (1-10 μM) or GW3965 (1-5 μM) for 24 h. Treating cells with T0901317 or GW3965 produced no effect on viability of HK-2 cells after 24 h of treatment (Fig. 1C) .
Inhibitory effect of LXR agonists on SGLT2 requires LXR and retinoid X receptor (RXR) activation
To determine whether the inhibitory effect of LXR agonist on SGLT2-mediated glucose uptake involved an LXR-dependent mechanism, fenofibrate (an LXR antagonist; Thomas et al. 2003 ) was applied to HK-2 cells. The cells were fasted for 12 h, then the cells were treated with six different treatments, as follows: (i) vehicle (0.1% DMSO); (ii) 10 μM T0901317; (iii) 5 μM GW3965; (iv) 10 μM fenofibrate; (v) 10 μM T0901317 plus 10 μM fenofibrate; and (vi) 5 μM GW3965 plus 10 μM fenofibrate. For groups (v) and (vi), the cells were pretreated with 10 μM fenofibrate for 4 h, followed by incubation with T0901317 or GW3965 plus fenofibrate for a further 24 h. After incubation, SGLT2-mediated glucose uptake was determined. As expected, T0901317 or GW3965 reduced SGLT2-mediated glucose uptake. Interestingly, fenofibrate significantly attenuated the inhibitory effects of both T0901317 and GW3965 (Fig. 2A) .
The LXR usually heterodimerizes with the RXR. We therefore determined whether RXR activation potentiated the inhibitory effect of the LXR. The cells were incubated in six different conditions, as follows: (i) vehicle (0.1% DMSO); (ii) 10 μM T0901317; (iii) 5 μM GW3965; (iv) 1 μM bexarotene (an RXR agonist); (v) 10 μM T0901317 plus 1 μM bexarotene; and (vi) 5 μM GW3965 plus 1 μM bexarotene. The results showed that bexarotene produced additional inhibitory effects of both T0901317 and GW3965 (Fig. 2B) .
Mechanism of LXR activation in regulating SGLT2-mediated glucose uptake
HK-2 cell monolayers were incubated with vehicle (0.1% DMSO), 10 μM T0901317 or 5 μM GW3965 for 24 h. The kinetic parameters, including J max and K t , were determined. As shown in Fig. 3 , treating the HK-2 cell monolayer with T0901317 or GW3965 significantly decreased J max , but not K t , of SGLT-mediated glucose uptake compared with vehicle control.
Effect of LXR activation on SGLT2 protein expression
Given that LXR activation inhibited [
3 H]-2DG transport in HK-2 cells, we determined whether it affected protein expression of SGLT2. Confluent monolayers of HK-2 cells were fasted for 12 h and then exposed to vehicle (0.1% DMSO), T0901317 (10 μM) or GW3965 (5 μM) for 24 h. The expression of SGLT2 was measured by Western blot analysis. As shown in Fig. 4, T0901317 and GW3965 significantly reduced SGLT2 expression in HK-2 cells compared with vehicle. To determine whether downregulation of SGLT2 was a result of gene expression, the effect of LXR activation on SGLT2 mRNA expression was determined. The results showed that treating HK-2 cell monolayers with T0901317 or GW3965 for 24 h had no effect on mRNA expression of SGLT2.
Effect of LXR activation on glucose transport in polarized renal proximal tubular cells
SGLT2-mediated glucose uptake is a rate-limiting step for transepithelial transport of glucose in renal proximal tubular cells. To determine the effect of LXR activation on transepithelial glucose transport, a polarized cell system (RPTEC/TERT1 cells) was used. First, the expression of SGLT2 in RPTEC/TERT1 cells expressing LXRα/β (Wongwan et al. 2017 ) was determined. The results showed that RPTEC/TERT1 cells highly expressed SGLT2 but weakly expressed SGLT1 (Fig. 5A) .
Next, the effect of LXR activation of SGLT2-mediated glucose transepithelial transport was determined by an electrophysiological study. Treating a cell monolayer growing on membrane inserts with 5 or 10 μM T0901317 for 24 h significantly reduced canagliflozin-sensitive I sc compared with vehicle treatment (Fig. 5B) . 
Effect of LXR activation on glucose uptake in renal proximal tubular cells in high-glucose conditions
The effect of LXR agonists on SGLT2-mediated uptake in HK-2 cells was determined after culturing cells in medium a high concentration of glucose (25 mM) for at least three passages. As shown in Fig. 6A , SGLT2-mediated [ 3 H]-2DG uptake in cells cultured in high-glucose conditions was higher than that of cells cultured in normal glucose conditions without a change in protein expression of SGLT2. To determine whether LXR activation could inhibit SGLT2 function in hyperglycaemic conditions, the effect of LXR agonists on SGLT2 was investigated. Cell monolayers were treated with vehicle (0.1% DMSO) or LXR agonists, T0901317 (10 μM) or GW3965 (5 μM), for 24 h in serum-free medium. Treatment of the cells with one of the LXR agonists significantly inhibited SGLT2-mediated [ 3 H]-2DG uptake (Fig. 6B) and decreased the protein expression of SGLT2 compared with the vehicle-treated group (Fig. 6C) . Values of the maximal rate of transport (J max ) and the concentration of unlabelled glucose that resulted in half-maximal transport (K t ) are means ± SD of three independent experiments. * P < 0.05 compared with control.
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Discussion
Renal SGLT2-mediated glucose reabsorption is a late-limiting step for renal glucose reabsorption, which is a key mechanism to prevent glucose loss (Hediger et al. 1995; Wright, 2001; Chao & Henry, 2010) . Accordingly, factors affecting transport function of SGLT2 will affect total renal glucose reabsorption and plasma glucose. Liver X receptors, as transcription factors, are likely to regulate the expression of the genes that encode those membrane transport proteins (Caldas et al. 2011; Gabbi et al. 2012; Kittayaruksakul et al. 2012; Soodvilai et al. 2012; Raksaseri et al. 2013; Lu et al. 2016) . Therefore, the role of LXRs in regulating renal glucose transporter-mediated uptake of glucose was investigated using pharmacological approaches. Although SGLT1 was found in HK-2 cells (Solocinski et al. 2015) , the contribution of SGLT1 to glucose transport in HK-2 cells may be minor, as evidence showed that mRNA expression of SGLT1 in HK-2 cells was very low compared with that of SGLT2. The present study unveils the new finding that LXR activation inhibits the transport function of SGLT2 in human renal proximal tubular cells. Uptake studies revealed that exposure of HK-2 cells to LXR agonists (T0901317 or GW3965) for 24 h led to a significant inhibition of SGLT2-mediated glucose uptake. As such, LXRs might be involved in the regulation of glucose uptake in human renal proximal tubular cells. The inhibitory effect of LXR agonist was attenuated by LXR antagonist, indicating that the inhibitory effects of LXR agonist required LXR activation. In addition, both LXR agonists had no significant effect on cell viability; therefore, the inhibitory effect of these agonists was not mediated by their toxicities. The RXR is a common partner of LXRs (Wan et al. 2000) ; we determined whether the RXR potentiated the effect of LXRs. In the presence of agonists of both RXR and LXR, an additive suppression of SGLT2 transport function was observed. These results indicate that LXR-RXR activation inhibits the transport function of SGLT2 in mediating glucose transport in renal proximal tubular cells. It should be noted that the results obtained from the present study rely on pharmacological approaches, and molecular approaches, using LXR or RXR knockdown cells, may be needed to strengthen the conclusion. Reduced membrane expression or affinity of transporters could contribute to a reduced transport function of membrane glucose transporters (Ghezzi & Wright, 2012) . To determine the mechanism responsible for downregulation of glucose transport induced by LXR activation, a kinetic study was performed. Cells treated with LXR agonists for 24 h had significantly reduced J max , but not K t , for SGLT2, suggesting that downregulation of SGLT2 may be mediated by reduced functional SGLT2 expression on the cell membrane. The reduction of SGLT2 expression could be a result of reducing the transporter synthesis. Western blot analysis revealed that activation of LXRs by T0901317 or GW3965 significantly decreased the total protein expression of SGLT2, indicating that LXR activation decreases protein expression of SGLT2. Although mRNA levels of SGLT2 would be expected to reduce in response to activation of LXR, interestingly, SGLT2 mRNA expression was not altered following LXR activation. These data indicated that SGLT2 might not be a direct target of LXR activation for transcriptional regulation. It has been reported that LXR activation regulates the low-density lipoprotein receptor via post-transcriptional regulation of lipoprotein receptors through ubiquitination (Sorrentino & Zelcer, 2012) . Therefore, modification of translational processes or protein degradation in the post-translational process of SGLT2 was suspected to be the target of LXR activation. This notion requires further investigation. Given that glucose uptake mediated by SGLT2 is a rate-limiting step for renal glucose reabsorption in intact tubules, an electrophysiological study was used to confirm the effect of LXR activation on SGLT2-mediated glucose in a polarized renal proximal tubular cell monolayer, which mimics the intact cell monolayer of renal proximal tubular cells. Although HK-2 cells show characteristics of renal proximal tubular cells, low transepithelial electrical resistance is observed when this cell line is cultured on a membrane insert (Wieser et al. 2008) . A new model of renal proximal tubular cells for P. Chonlaket and others determining transepithelial transport, the RPTEC/TERT1 cell line, was piloted because it shows expression of SGLT2 and high transepithelial electrical resistance when cultured on a membrane insert. As expected, LXR agonist reduces canagliflozin-sensitive I sc , representing the sodium-glucose cotransport mechanism. These data indicate that LXR activation inhibits SGLT2-mediated transport of glucose in a polarized renal proximal tubular cell monolayer.
Although hyperglycaemic conditions increase glucose transport in renal proximal tubular cells via induction of expression of SGLT2 and GLUT2 to increase glucose reabsorption in diabetic mice (Marks et al. 2003; Vallon et al. 2013) , our data showed that high-glucose conditions did not stimulate protein expression of SGLT2, but increased transport function in HK-2 cells. This phenomenon might be an adaptive process to limit glucose accumulation, because the experimental model used in this study is non-polarized cells that have no vectorial transport of glucose. Hyperglycaemia-induced upregulation of PKC and PKA might implicate an increase in SGLT2 function (Park et al. 2001; Ghezzi & Wright, 2012; Deb et al. 2017) . We determined whether the inhibitory effect of LXR on SGLT2 transport function existed in hyperglycaemic conditions. The effect of LXR activation on SGLT2-mediated glucose uptake in high-glucose conditions was determined. Our data showed that the transport function and protein expression of SGLT2 were reduced during LXR activation in high-glucose conditions, as found in low glucose. These data indicate that LXR impacts regulation of SGLT2 in hyperglycaemic conditions. In summary, LXR activation regulates renal glucose transport by decreasing SGLT2 transport function in human renal proximal cells in both normal and high-glucose conditions. The inhibitory effect of LXR activation on glucose transport is mediated by downregulation of SGLT2 protein expression. This is evidence for LXR involvement in the regulation of SGLT2-mediated glucose transport in human renal proximal tubular cells.
